DynaMMic-1NCT05714839
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 60 words
- Trial sites expanded: 44 → 59 locations
Notable Primary endpoint(s) modifiedv9 Show 4 more changesShow less
- Eligibility criteria expanded, about 172 words
- Trial sites expanded: 36 → 44 locations
- Interventions: Belantamab mafodotin (Drug), Unconjugated belantamab antibody (Drug), Unconjugated belantamab antibody and belantamab mafodotin (Drug)… to Belantamab (Drug), Belantamab mafodotin (Drug), Dexamethasone (Drug), Pomalidomide (Drug)
- Secondary endpoints revised (26)
Notable Primary and study completion moved earlier from Dec 3, 2029 to Aug 3, 2028v8 Show 6 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 74 words
- Enrollment reduced: 152 → 123 participants
- Trial sites expanded: 30 → 36 locations
- Interventions: Belantamab mafodotin (Drug), Unconjugated belantamab antibody (Drug), Unconjugated belantamab antibody and belantamab mafodotin (Drug)… to Belantamab mafodotin (Drug), Unconjugated belantamab antibody (Drug), Unconjugated belantamab antibody and belantamab mafodotin (Drug)…
- Secondary endpoints: 31 to 26
- Minor Trial sites expanded: 27 → 30 locations
- Enrollment target: 153 to 152
Notable Phase: Phase 1 to Phase 1/2v6 Show 7 more changesShow less
- Enrollment target: 55 to 153
- Eligibility criteria expanded, about 608 words
- Primary endpoints: 5 to 6
- Study sites: 21 to 27
- Interventions: Belantamab (Drug), Belantamab and belantamab mafodotin (Drug), Belantamab mafodotin (Drug) to Belantamab mafodotin (Drug), Unconjugated belantamab antibody (Drug), Unconjugated belantamab antibody and belantamab mafodotin (Drug)…
- Secondary endpoints: 18 to 31
- Study arms: 3 to 4
Show 4 earlier versionsHide 4 earlier versions
- Minor Enrollment target: 48 to 55
- Study sites: 15 to 21
Notable Primary and study completion dates: Sep 19, 2028 to Dec 3, 2029v4 Show 4 more changesShow less
- Eligibility criteria expanded, about 42 words
- Primary endpoints revised (5)
- Study sites: 20 to 15
- Start date: May 31, 2023 to Jun 14, 2023
Notable Enrollment target: 124 to 48v3 Show 7 more changesShow less
- Primary and study completion dates pushed to Sep 19, 2028
- Eligibility criteria expanded, about 503 words
- Primary endpoints: 4 to 5
- Study sites: 17 to 20
- Start date: Jun 14, 2023 to May 31, 2023
- Interventions: Bela (Drug), Belamaf (Drug), Dexamethasone (Drug), Lenalidomide (Drug), Standard of Care (Drug) to Belantamab (Drug), Belantamab and belantamab mafodotin (Drug), Belantamab mafodotin (Drug)
- Secondary endpoints: 12 to 18
Notable Phase: Phase 1/2 to Phase 1v2 Show 5 more changesShow less
- Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Feb 28, 2023 to Jun 14, 2023
- Study sites: 0 to 17
- Primary completion date: Jun 28, 2027 to Sep 29, 2027
- Study completion date: Jun 28, 2027 to Feb 29, 2028
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (26)
Show 21 moreShow less
Arms and interventions
Belantamab will be administered in participants with RRMM until progressive disease (PD)
Participants with RRMM will receive belantamab and belantamab mafodotin
Participants with RRMM will receive belantamab in combination with pomalidomide-dexamethasone backbone.
Participants enrolled in Part 1 and Part 2 will be dosed until PD after which they will have the option to receive treatment with single agent belantamab mafodotin.
Drugs: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone
Sites
59 sites in 15 countries
United States 12, Japan 7, Argentina 6, Israel 6, Finland 4, Turkey (Türkiye) 4, Brazil 3, Taiwan 3, United Kingdom 3, Australia 2, China 2, Poland 2, South Africa 2, South Korea 2, Germany 1